{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:33:41Z","timestamp":1788993221963,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T00:00:00Z","timestamp":1595635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T00:00:00Z","timestamp":1595635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s00262-020-02664-y","type":"journal-article","created":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T12:02:33Z","timestamp":1595678553000},"page":"299-309","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Improved survival in patients with thyroid function test abnormalities secondary to immune-checkpoint inhibitors"],"prefix":"10.1007","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8405-7682","authenticated-orcid":false,"given":"Joana","family":"Lima Ferreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e1udia","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarida","family":"Victor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Paula","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00eas Lucena","family":"Sampaio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Paula","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,25]]},"reference":[{"key":"2664_CR1","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40618-017-0778-8","volume":"41","author":"P Chalan","year":"2018","unstructured":"Chalan P, Di Dalmazi G, Pani F, De Remigis A, Corsello A, Caturegli P (2018) Thyroid dysfunctions secondary to cancer immunotherapy. J Endocrinol Invest 41:625\u2013638. https:\/\/doi.org\/10.1007\/s40618-017-0778-8","journal-title":"J Endocrinol Invest"},{"key":"2664_CR2","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252\u2013264. https:\/\/doi.org\/10.1038\/nrc3239","journal-title":"Nat Rev Cancer"},{"key":"2664_CR3","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1146\/annurev-med-092012-112807","volume":"65","author":"DB Page","year":"2014","unstructured":"Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD (2014) Immune modulation in cancer with antibodies. Annu Rev Med 65:185\u2013202. https:\/\/doi.org\/10.1146\/annurev-med-092012-112807","journal-title":"Annu Rev Med"},{"key":"2664_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","volume":"62","author":"KM Hargadon","year":"2018","unstructured":"Hargadon KM, Johnson CE, Williams CJ (2018) Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol 62:29\u201339. https:\/\/doi.org\/10.1016\/j.intimp.2018.06.001(S1567-5769(18)30252-2 [pii])","journal-title":"Int Immunopharmacol"},{"key":"2664_CR5","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s11154-018-9463-2","volume":"19","author":"SM Ferrari","year":"2018","unstructured":"Ferrari SM, Fallahi P, Galetta F, Citi E, Benvenga S, Antonelli A (2018) Thyroid disorders induced by checkpoint inhibitors. Rev Endocr Metab Disord 19:325\u2013333. https:\/\/doi.org\/10.1007\/s11154-018-9463-2","journal-title":"Rev Endocr Metab Disord"},{"key":"2664_CR6","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/annonc\/mdw640","volume":"28","author":"JC Osorio","year":"2017","unstructured":"Osorio JC, Ni A, Chaft JE et al (2017) Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol 28:583\u2013589. https:\/\/doi.org\/10.1093\/annonc\/mdw640","journal-title":"Ann Oncol"},{"key":"2664_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-019-01112-8","author":"EM Presotto","year":"2019","unstructured":"Presotto EM, Rastrelli G, Desideri I et al (2019) Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study. J Endocrinol Invest. https:\/\/doi.org\/10.1007\/s40618-019-01112-8","journal-title":"J Endocrinol Invest"},{"key":"2664_CR8","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/CCO.0000000000000290","volume":"28","author":"V Sibaud","year":"2016","unstructured":"Sibaud V, Meyer N, Lamant L, Vigarios E, Mazieres J, Delord JP (2016) Dermatologic complications of anti-PD-1\/PD-L1 immune checkpoint antibodies. Curr Opin Oncol 28:254\u2013263. https:\/\/doi.org\/10.1097\/CCO.0000000000000290","journal-title":"Curr Opin Oncol"},{"key":"2664_CR9","doi-asserted-by":"publisher","first-page":"e0160221","DOI":"10.1371\/journal.pone.0160221","volume":"11","author":"N Abdel-Wahab","year":"2016","unstructured":"Abdel-Wahab N, Shah M, Suarez-Almazor ME (2016) Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports. PLoS ONE 11:e0160221. https:\/\/doi.org\/10.1371\/journal.pone.0160221","journal-title":"PLoS ONE"},{"key":"2664_CR10","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jaad.2014.02.035","volume":"71","author":"ME Lacouture","year":"2014","unstructured":"Lacouture ME, Wolchok JD, Yosipovitch G, Kahler KC, Busam KJ, Hauschild A (2014) Ipilimumab in patients with cancer and the management of dermatologic adverse events. J Am Acad Dermatol 71:161\u2013169. https:\/\/doi.org\/10.1016\/j.jaad.2014.02.035(S0190-9622(14)01152-9[pii])","journal-title":"J Am Acad Dermatol"},{"key":"2664_CR11","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1470-2045(16)30126-7","volume":"17","author":"JS Weber","year":"2016","unstructured":"Weber JS, Gibney G, Sullivan RJ et al (2016) Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol 17:943\u2013955. https:\/\/doi.org\/10.1016\/S1470-2045(16)30126-7(S1470-2045(16)30126-7[pii])","journal-title":"Lancet Oncol"},{"key":"2664_CR12","doi-asserted-by":"publisher","first-page":"225","DOI":"10.14740\/jocmr3750","volume":"11","author":"R Bajwa","year":"2019","unstructured":"Bajwa R, Cheema A, Khan T et al (2019) Adverse effects of immune checkpoint inhibitors (programmed death-1 inhibitors and cytotoxic T-lymphocyte-associated protein-4 inhibitors): results of a retrospective study. J Clin Med Res 11:225\u2013236. https:\/\/doi.org\/10.14740\/jocmr3750","journal-title":"J Clin Med Res"},{"key":"2664_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2533","author":"E Kassi","year":"2019","unstructured":"Kassi E, Angelousi A, Asonitis N et al (2019) Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma. Cancer Med. https:\/\/doi.org\/10.1002\/cam4.2533","journal-title":"Cancer Med"},{"key":"2664_CR14","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1530\/EJE-17-0810","volume":"178","author":"ES Scott","year":"2018","unstructured":"Scott ES, Long GV, Guminski A, Clifton-Bligh RJ, Menzies AM, Tsang VH (2018) The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma. Eur J Endocrinol 178:173\u2013180. https:\/\/doi.org\/10.1530\/EJE-17-0810","journal-title":"Eur J Endocrinol"},{"key":"2664_CR15","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s12020-019-01871-7","volume":"64","author":"I Peiro","year":"2019","unstructured":"Peiro I, Palmero R, Iglesias P et al (2019) Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes. Endocrine 64:605\u2013613. https:\/\/doi.org\/10.1007\/s12020-019-01871-7","journal-title":"Endocrine"},{"key":"2664_CR16","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.ando.2018.07.007","volume":"79","author":"F Illouz","year":"2018","unstructured":"Illouz F, Drui D, Caron P, Do Cao C (2018) Expert opinion on thyroid complications in immunotherapy. Ann Endocrinol (Paris) 79:555\u2013561. https:\/\/doi.org\/10.1016\/j.ando.2018.07.007(S0003-4266(18)31185-5[pii])","journal-title":"Ann Endocrinol (Paris)"},{"key":"2664_CR17","doi-asserted-by":"publisher","first-page":"e199","DOI":"10.1016\/j.lpm.2018.10.019","volume":"48","author":"P Campredon","year":"2019","unstructured":"Campredon P, Mouly C, Lusque A, Bigay-Game L, Bousquet E, Mazieres J, Caron P (2019) Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: retrospective study of 105 patients. Presse Med 48:e199\u2013e207. https:\/\/doi.org\/10.1016\/j.lpm.2018.10.019(S0755-4982(19)30088-0[pii])","journal-title":"Presse Med"},{"key":"2664_CR18","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1634\/theoncologist.2017-0375","volume":"23","author":"NS Patel","year":"2018","unstructured":"Patel NS, Oury A, Daniels GA, Bazhenova L, Patel SP (2018) Incidence of thyroid function test abnormalities in patients receiving immune-checkpoint inhibitors for cancer treatment. Oncologist 23:1236\u20131241. https:\/\/doi.org\/10.1634\/theoncologist.2017-0375","journal-title":"Oncologist"},{"key":"2664_CR19","doi-asserted-by":"publisher","DOI":"10.4158\/EP-2019-0244","author":"M Al Mushref","year":"2019","unstructured":"Al Mushref M, Guido PA, Collichio FA, Moore DT, Clemmons DR (2019) Thyroid dysfunction, recovery, and prognosis in melanoma patients treated with immune checkpoint inhibitors: a retrospective review. Endocr Pract. https:\/\/doi.org\/10.4158\/EP-2019-0244","journal-title":"Endocr Pract"},{"key":"2664_CR20","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/cen.13297","volume":"86","author":"DL Morganstein","year":"2017","unstructured":"Morganstein DL, Lai Z, Spain L, Diem S, Levine D, Mace C, Gore M, Larkin J (2017) Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. Clin Endocrinol (Oxf) 86:614\u2013620. https:\/\/doi.org\/10.1111\/cen.13297","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2664_CR21","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s40618-017-0772-1","volume":"41","author":"F Guaraldi","year":"2018","unstructured":"Guaraldi F, La Selva R, Sama MT, D'Angelo V, Gori D, Fava P, Fierro MT, Savoia P, Arvat E (2018) Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution. J Endocrinol Invest 41:549\u2013556. https:\/\/doi.org\/10.1007\/s40618-017-0772-1","journal-title":"J Endocrinol Invest"},{"key":"2664_CR22","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1210\/jc.2014-2306","volume":"99","author":"AT Faje","year":"2014","unstructured":"Faje AT, Sullivan R, Lawrence D, Tritos NA, Fadden R, Klibanski A, Nachtigall L (2014) Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab 99:4078\u20134085. https:\/\/doi.org\/10.1210\/jc.2014-2306","journal-title":"J Clin Endocrinol Metab"},{"key":"2664_CR23","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1530\/EJE-14-0845","volume":"172","author":"F Albarel","year":"2015","unstructured":"Albarel F, Gaudy C, Castinetti F, Carre T, Morange I, Conte-Devolx B, Grob JJ, Brue T (2015) Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol 172:195\u2013204. https:\/\/doi.org\/10.1530\/EJE-14-0845","journal-title":"Eur J Endocrinol"},{"key":"2664_CR24","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M et al (2017) Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 377:1824\u20131835. https:\/\/doi.org\/10.1056\/NEJMoa1709030","journal-title":"N Engl J Med"},{"key":"2664_CR25","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ejim.2017.08.019","volume":"47","author":"P Iglesias","year":"2018","unstructured":"Iglesias P (2018) Cancer immunotherapy-induced endocrinopathies: clinical behavior and therapeutic approach. Eur J Intern Med 47:6\u201313. https:\/\/doi.org\/10.1016\/j.ejim.2017.08.019(S0953-6205(17)30321-7[pii])","journal-title":"Eur J Intern Med"},{"key":"2664_CR26","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jemermed.2018.07.005","volume":"55","author":"AT Hryniewicki","year":"2018","unstructured":"Hryniewicki AT, Wang C, Shatsky RA, Coyne CJ (2018) Management of immune checkpoint inhibitor toxicities: a review and clinical guideline for emergency physicians. J Emerg Med 55:489\u2013502. https:\/\/doi.org\/10.1016\/j.jemermed.2018.07.005(S0736-4679(18)30660-7[pii])","journal-title":"J Emerg Med"},{"key":"2664_CR27","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","volume":"7","author":"S Das","year":"2019","unstructured":"Das S, Johnson DB (2019) Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer 7:306. https:\/\/doi.org\/10.1186\/s40425-019-0805-8","journal-title":"J Immunother Cancer"},{"key":"2664_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2019.05.020","volume":"66","author":"A Barquin-Garcia","year":"2019","unstructured":"Barquin-Garcia A, Molina-Cerrillo J, Garrido P, Garcia-Palos D, Carrato A, Alonso-Gordoa T (2019) New oncologic emergencies: What is there to know about inmunotherapy and its potential side effects? Eur J Intern Med 66:1\u20138. https:\/\/doi.org\/10.1016\/j.ejim.2019.05.020(S0953-6205(19)30178-5[pii])","journal-title":"Eur J Intern Med"},{"key":"2664_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40842-018-0073-4","volume":"5","author":"MH Tan","year":"2019","unstructured":"Tan MH, Iyengar R, Mizokami-Stout K, Yentz S, MacEachern MP, Shen LY, Redman B, Gianchandani R (2019) Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports. Clin Diabetes Endocrinol 5:1. https:\/\/doi.org\/10.1186\/s40842-018-0073-4","journal-title":"Clin Diabetes Endocrinol"},{"key":"2664_CR30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1210\/er.2018-00006","volume":"40","author":"LS Chang","year":"2019","unstructured":"Chang LS, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L (2019) Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev 40:17\u201365. https:\/\/doi.org\/10.1210\/er.2018-00006","journal-title":"Endocr Rev"},{"key":"2664_CR31","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/cncr.31200","volume":"124","author":"R Barroso-Sousa","year":"2018","unstructured":"Barroso-Sousa R, Ott PA, Hodi FS, Kaiser UB, Tolaney SM, Min L (2018) Endocrine dysfunction induced by immune checkpoint inhibitors: practical recommendations for diagnosis and clinical management. Cancer 124:1111\u20131121. https:\/\/doi.org\/10.1002\/cncr.31200","journal-title":"Cancer"},{"key":"2664_CR32","doi-asserted-by":"publisher","first-page":"pky021","DOI":"10.1093\/jncics\/pky021","volume":"2","author":"M Girotra","year":"2018","unstructured":"Girotra M, Hansen A, Farooki A et al (2018) The current understanding of the endocrine effects from immune checkpoint inhibitors and recommendations for management. JNCI Cancer Spectr 2:pky021. https:\/\/doi.org\/10.1093\/jncics\/pky021","journal-title":"JNCI Cancer Spectr"},{"key":"2664_CR33","doi-asserted-by":"publisher","first-page":"e14096","DOI":"10.1200\/JCO.2019.37.15_suppl.e14096","volume":"37","author":"C Gomes-Lima","year":"2019","unstructured":"Gomes-Lima C, Kwagyan J, King F, Fernandez S, Burman K, Veytsman I (2019) A comprehensive meta-analysis of endocrine immune-related adverse events of immune checkpoint inhibitors and outcomes in head and neck cancer and lung cancer. J Clin Oncol 37:e14096. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.e14096","journal-title":"J Clin Oncol"},{"key":"2664_CR34","doi-asserted-by":"publisher","first-page":"e1375642","DOI":"10.1080\/2162402X.2017.1375642.1375642[pii]","volume":"7","author":"HI Kim","year":"2017","unstructured":"Kim HI, Kim M, Lee SH et al (2017) Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer. Oncoimmunology 7:e1375642. https:\/\/doi.org\/10.1080\/2162402X.2017.1375642.1375642[pii]","journal-title":"Oncoimmunology"},{"key":"2664_CR35","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/nature07662","volume":"458","author":"V Velu","year":"2009","unstructured":"Velu V, Titanji K, Zhu B et al (2009) Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 458:206\u2013210. https:\/\/doi.org\/10.1038\/nature07662","journal-title":"Nature"},{"key":"2664_CR36","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0075","author":"A Kotwal","year":"2020","unstructured":"Kotwal A, Gustafson MP, Bornschlegl S, Kottschade L, Delivanis DA, Dietz AB, Gandhi M, Ryder M (2020) Immune checkpoint inhibitor-induced thyroiditis is associated with increased intrathyroidal T lymphocyte subpopulations. Thyroid. https:\/\/doi.org\/10.1089\/thy.2020.0075","journal-title":"Thyroid"},{"key":"2664_CR37","doi-asserted-by":"publisher","first-page":"3934","DOI":"10.3390\/ijms20163934","volume":"20","author":"G Varricchi","year":"2019","unstructured":"Varricchi G, Loffredo S, Marone G, Modestino L, Fallahi P, Ferrari SM, de Paulis A, Antonelli A, Galdiero MR (2019) The immune landscape of thyroid cancer in the context of immune checkpoint inhibition. Int J Mol Sci 20:3934. https:\/\/doi.org\/10.3390\/ijms20163934","journal-title":"Int J Mol Sci"},{"key":"2664_CR38","doi-asserted-by":"publisher","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","volume":"13","author":"SG Downey","year":"2007","unstructured":"Downey SG, Klapper JA, Smith FO et al (2007) Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 13:6681\u20136688. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-0187","journal-title":"Clin Cancer Res"},{"key":"2664_CR39","doi-asserted-by":"publisher","first-page":"W992","DOI":"10.2214\/AJR.10.6198","volume":"197","author":"Y Bronstein","year":"2011","unstructured":"Bronstein Y, Ng CS, Hwu P, Hwu WJ (2011) Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. AJR Am J Roentgenol 197:W992\u2013W1000. https:\/\/doi.org\/10.2214\/AJR.10.6198","journal-title":"AJR Am J Roentgenol"},{"key":"2664_CR40","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1158\/1078-0432.CCR-10-2463","volume":"17","author":"AA Sarnaik","year":"2011","unstructured":"Sarnaik AA, Yu B, Yu D et al (2011) Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc\/IV melanoma. Clin Cancer Res 17:896\u2013906. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2463","journal-title":"Clin Cancer Res"},{"key":"2664_CR41","doi-asserted-by":"publisher","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-09-1024","volume":"15","author":"J Weber","year":"2009","unstructured":"Weber J, Thompson JA, Hamid O et al (2009) A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 15:5591\u20135598. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-1024","journal-title":"Clin Cancer Res"},{"key":"2664_CR42","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1200\/JCO.2017.73.2289","volume":"35","author":"D Schadendorf","year":"2017","unstructured":"Schadendorf D, Wolchok JD, Hodi FS et al (2017) Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol 35:3807\u20133814. https:\/\/doi.org\/10.1200\/JCO.2017.73.2289","journal-title":"J Clin Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02664-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-020-02664-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02664-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T23:14:29Z","timestamp":1627168469000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-020-02664-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,25]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["2664"],"URL":"https:\/\/doi.org\/10.1007\/s00262-020-02664-y","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,25]]},"assertion":[{"value":"20 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest, namely relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This research study was conducted retrospectively from data obtained for clinical purposes. This study was approved by the Local Ethical Committee of the Instituto Portugu\u00eas de Oncologia do Porto (CES.180\/020)\u00a0and has been performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was not obtained from each patient, because this retrospective analysis of existing data did not require any interaction with patients and did not intervene in their treatment.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}